2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 261

Sarcoidosis Is Associated with Increased Risk of Venous Thromboembolism: A Population-Based Study
Abstract Number: 1631

Sarilumab Dose Reduction in an Open-Label Extension Study in RA Patients
Abstract Number: 3179

Scale Structure and Measurement Properties of a Disease Specific Patient-Reported Outcome for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Abstract Number: 2717

Sclerostin and Dickkopf-1 but Not Periostin May Have a Role in Psoriatic Arthritis
Abstract Number: 3160

Scoring Syndesmophytes on CT Spine Images of Patients with Radiographic Axial Spondyloarthritis from the Sensitive Imaging of Axial Spondyloarthritis (SIAS) Cohort
Abstract Number: 2050

Screening for and Management of Comorbidities after a Nurse-Led Program: Results of a 3 Year Longitudinal Study in 776 Established RA Patients
Abstract Number: 1173

Screening for Depression and Anxiety in an Outpatient Rheumatology Clinic Using Validated Self-Applied Questionnaires
Abstract Number: 1901

Screening for Pulmonary Arterial Hypertension in an Unselected Prospective Systemic Sclerosis Cohort
Abstract Number: 1493

Screening Patterns for Hyperlipidemia Among Patients with Rheumatoid Arthritis Based on Patterns of Care from By Primary Care Physicians, Rheumatologists or Both
Abstract Number: 1797

Seasonal Differences in the Disease Onset and the Exacerbation of Systemic Lupus Erythematosus
Abstract Number: 262

Seasonal Variation in Incidence of Sarcoidosis: A Population-Based Study 1976-2013
Abstract Number: 3163

SEC16A and Intracellular Trafficking Abnormalities in Axial Spondyloarthritis
Abstract Number: 1738

Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Versus Adalimumab Using a Matching-Adjusted Indirect Comparison
Abstract Number: 1729

Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Versus Infliximab Using a Matching-Adjusted Indirect Comparison
Abstract Number: 961

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis through 3 Years: Efficacy and Safety Results from a Phase 3 Trial

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].